These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Osimertinib for Secondary T790M-Mutation-Positive Squamous Cell Carcinoma Transformation After Afatinib Failure. Kong M; Sung JY; Lee SH J Thorac Oncol; 2018 Dec; 13(12):e252-e254. PubMed ID: 30467047 [No Abstract] [Full Text] [Related]
3. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382 [TBL] [Abstract][Full Text] [Related]
4. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. Lee K; Kim D; Yoon S; Lee DH; Kim SW Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716 [TBL] [Abstract][Full Text] [Related]
5. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation. Chiang CL; Yeh YC; Chou TY; Chiu CH J Formos Med Assoc; 2020 Sep; 119(9):1439-1441. PubMed ID: 32173232 [No Abstract] [Full Text] [Related]
6. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539 [TBL] [Abstract][Full Text] [Related]
7. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138 [TBL] [Abstract][Full Text] [Related]
8. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441 [TBL] [Abstract][Full Text] [Related]
9. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study. Wang X; Cai J; Zeng Z; Liu A BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231 [TBL] [Abstract][Full Text] [Related]
11. Osimertinib 160 mg daily for advanced non-small cell lung cancer with leptomeningeal metastasis: A case report. Tsang MW Asia Pac J Clin Oncol; 2019 Oct; 15 Suppl 6():5-7. PubMed ID: 31642175 [TBL] [Abstract][Full Text] [Related]
12. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis. Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465 [TBL] [Abstract][Full Text] [Related]
13. Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations. Ikari T; Sakakibara-Konishi J; Yamamoto G; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N Clin Lung Cancer; 2019 Jul; 20(4):e531-e533. PubMed ID: 31164318 [No Abstract] [Full Text] [Related]
14. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation. Okuno T; Arakawa S; Yoshida T; Ohe Y Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253 [No Abstract] [Full Text] [Related]
16. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345 [TBL] [Abstract][Full Text] [Related]
17. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714 [TBL] [Abstract][Full Text] [Related]
18. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210 [TBL] [Abstract][Full Text] [Related]
19. Osimertinib confers potent binding affinity to EGFR kinase domain duplication. Jin R; Li J; Jin Z; Lu Y; Shao YW; Li W; Zhao G; Xia Y Int J Cancer; 2019 Nov; 145(10):2884-2885. PubMed ID: 31393596 [No Abstract] [Full Text] [Related]
20. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]